Published September 2, 2024 | Version v1
Journal article Open

Cataloging health state utility estimates for Duchenne muscular dystrophy and related conditions

  • 1. Tufts Medical Center
  • 2. Sarepta Therapeutics, Inc.
  • 3. University of Chicago

Description

Background: Duchenne muscular dystrophy (DMD) is a genetic disease resulting in progressive muscle weakness, loss of ambulation, and cardiorespiratory complications. Direct estimation of health-related quality of life for patients with DMD is challenging, highlighting the need for proxy measures. This study aims to catalog and compare existing published health state utility estimates for DMD and related conditions.

Methods: Using two search strategies, relevant utilities were extracted from the Tufts Cost-Effectiveness Analysis Registry, including health states, utility estimates, and study and patient characteristics. Analysis One identified health states with comparable utility estimates to a set of published US patient population utility estimates for DMD. A minimal clinically important difference of ± 0.03 was applied to each DMD utility estimate to establish a range, and the registry was searched to identify other health states with associated utilities that fell within each range. Analysis Two used pre-defined search terms to identify health states clinically similar to DMD. Mapping was based on the degree of clinical similarity.

Results: Analysis One identified 4,308 unique utilities across 2,322 cost-effectiveness publications. The health states captured a wide range of acute and chronic conditions; 34% of utility records were extrapolated for US populations (n = 1,451); 1% were related to pediatric populations (n = 61). Analysis Two identified 153 utilities with health states clinically similar to DMD. The median utility estimates varied among identified health states. Health states similar to the early non-ambulatory DMD phase exhibited the greatest difference between the median estimate of the sample (0.39) and the existing estimate from published literature (0.21).

Conclusions: When available estimates are limited, using novel search strategies to identify utilities of clinically similar conditions could be an approach for overcoming the information gap. However, it requires careful evaluation of the utility instruments, tariffs, and raters (proxy or self).

Data availability

The datasets used during the current study are available from the corresponding author on reasonable request.

Files

Cataloging-health-state-utility-estimates-for-Duchenne-muscular-dystrophy-and-related-conditions.pdf

Files (2.9 MB)

Name Size Download all
Supplementary material
md5:abf16cd4977cf93107b0c606442798de
1.4 MB Preview Download
Article
md5:89f71ed758ce86f76d816f983ff3d469
1.5 MB Preview Download

Additional details

Identifiers

DOI
10.1186/s12955-024-02287-2
Other
oai:uchicago.tind.io:13357

Funding

Sarepta Therapeutics, Inc.

UChicago Information

Division(s)
Biological Sciences Division
Department(s)
Medicine